<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881970</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01018-37</org_study_id>
    <secondary_id>2013-32</secondary_id>
    <nct_id>NCT02881970</nct_id>
  </id_info>
  <brief_title>Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells</brief_title>
  <acronym>NEOSTEM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal hypoxic-ischaemic encephalopathy is a dramatic perinatal complication due to brain
      asphyxia. Neurological and neurosensory sequelae are frequent in survivors, due to neuronal
      damage and loss.

      Currently, only total or partial body hypothermia can partially prevent cell loss. However,
      no treatment exists to restore neuronal functions.

      Cord blood stem cells are a promising treatment for the near future.

      The primary objective of this study is to test the safety and feasibility of a curative
      treatment with autologous cord blood stem cell in neonatal hypoxic-ischaemic encephalopathy.

      The secondary objectives are to test the efficacy of this curative treatment with cell with
      neurogenic potential on the prevention of neurologic sequelae, as well as to test the optimum
      timing of cell preparation administration
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse clinical or paraclinical event rates due to stem cell preparation</measure>
    <time_frame>2years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Preliminary efficacy as measured by neurodevelopmental function</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neonatal Hypoxic-ischaemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Neonatal hypoxic-ischaemic encephalopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous cord blood stem cell</intervention_name>
    <arm_group_label>Neonatal hypoxic-ischaemic encephalopathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Term ≥ 36 weeks of gestation

          -  and (2) :

          -  a blood pH &lt; 7 with base deficit &gt; 12 mmol/l (at birth or within 60 minutes of age)

          -  or a blood pH between 7,01 and 7,15, with additionnal criteria:

          -  a history of acute perinatal event (e.g : abnormal fetal cardiac rate, cord prolapse,
             uterine rupture, maternal hemorrhage)

          -  and a 5 minutes Apgar score ≤ 5, or a continued need for resuscitation, including
             endotracheal or mask ventilation at 5 min after birth.

          -  signs of encephalopathy within 12 hours of age (Sarnat and Sarnat classification,
             score ≥ 2)

          -  ± abnormal electroencephalogram or aEEG within 12 hours of age

          -  therapeutic hypothermia.

          -  no maternal infection with VIH, HTLV 1 or 2, Hepatitis B or C virus.

          -  maternal negative serology for syphilis

          -  written parental consent

        Exclusion Criteria:

          -  presence of known chromosomal anomaly.

          -  presence of major congenital anomalies. severe intrauterine growth restriction (weight
             &lt;1800g)

          -  infants in extremis for whom no additional intensive therapy will be offered by
             attending neonatologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CATHERINE GEINDRE</last_name>
    <role>Study Director</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farid BOUBRED</last_name>
    <email>farid.boubrd@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FARID BOUBRED</last_name>
      <email>farid.boubred@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

